NPCE · NeuroPace Inc
$13.68
-1.64 (-10.68%)
At close · Jul 29
Market Cap
$521.98M
Shares
34.09M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$15.31
Open$15.53
Day$15.20–15.83
52W$7.56–19.60
Avg vol 30d173K
Short int874K · 2.6% float · 5.7d
Short vol23%
Last earningsMay 12, 2026
DataApr 2021–Jul 2026
Filing10-Q · May 12
Up next
Next earnings call
Aug 8, 2026
Est · unconfirmed
· in 1 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 12, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+2%
above
Price vs 50-day avg
−5%
below
RSI (14)
44
neutral
MACD trend
Negative
52-week position
64%
mid-range
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−7%
trailing
6-month return
−4%
trailing
YTD return
−1%
this year
Relative strength
−11%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $16 › 200d $15 — 50d above 200d
Institutional flow
Accumulating
12 of 112 funds reported for Jun 30 · net +2.6K sh shares · +3 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.56% of float · ▼ -2.7% MoM · 5.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
112 holders — near 3-yr high, broad support
Squeeze score
56
elevated · 0–100
Fundamentals
Revenue growth
+25%
Y/Y
Gross margin
77%
expanding
EPS growth
+29%
Y/Y
Free cash flow
$-11.3M
Balance sheet
$37.2M
net debt
Quant / Vol
risk profile
Volatility
62%
annualized · 1-yr
Max drawdown
−26%
past year
ATR
5.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 12, 2026
Full year 2026 guidance
· full year 2026
Initiated
$99M – $101M
prior FY $99.99M
midpoint +0.0% Y/Y
Guided vs delivered
· last 2 settled
Revenue
full year
guided $97M – $98M
$99.99M
Beat +2.5%
Total revenue
2024
guided $78M – $80M
$79.91M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+2%
Bullish
Price vs 50-day avg
−5%
Neutral
RSI (14)
44
Neutral
MACD trend
Negative
Bearish
52-week position
64%
Neutral
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $16 › 200d $15 — 50d above 200d
Institutional flow
Accumulating
12 of 112 funds reported for Jun 30 · net +2.6K sh shares · +3 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.56% of float · ▼ -2.7% MoM · 5.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
112 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $8
Now $15 · 64%
52-wk high $20
vs 200-day avg +2%
vs 50-day avg -5%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Non-GAAP gross margin non-GAAP | 82.5% | Q1 2026 | — |
| Adjusted EBITDA non-GAAP | $0.9M | the fourth quarter of 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NPCE
this stock
NeuroPace Inc
|
$521.98M | -0.8% | +25.1% | — | 2.6% |
|
ABT
Abbott Laboratories
|
$186.84B | -13.9% | +5.7% | 30.1 | 1.4% |
|
SYK
Stryker Corp
|
$132.87B | -1.1% | +11.2% | 40.1 | 1.8% |
|
MDT
Medtronic plc
|
$111.21B | -8.8% | +8.4% | 23.3 | 1.5% |
|
BSX
Boston Scientific Corp
|
$68.43B | -51.7% | +5.5% | 19.3 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NPCE | -2.8% | -7.0% | -3.8% | -3.7% | -0.8% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | -1.8% | -7.0% | -11.2% | -2.9% | -9.5% |
Key facts
CIK
1528287
CUSIP
641288105
13F (30d)
10 filings
10 filers
Visit website
Investor relations